Tofacitnib for the Treatment of Alopecia Areata and Variants
Part of paid clinical trials in New Haven, Connecticut.
- Sponsor
- Yale University
- Study ID
- NCT02197455
- Phase
- PHASE2
- Status
- Completed
Conditions
- Alopecia Areata (AA)
- Alopecia Totalis (AT)
- Alopecia Universalis (AU)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 90 Years
- Healthy Volunteers
- Not accepted
Interventions
- Tofacitinib Administration — DRUG5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
Study Details
The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.
Key Dates
- Start date
- Jul 31, 2014
- Status verified
- Mar 2017
- Primary completion
- Jul 31, 2015
- Completion
- Jul 31, 2015
Study Design
- Enrollment
- 30 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Tofacitinib Administration5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
Primary Outcome Measure
Mean Change in Severity of Alopecia Tool (SALT) Score [ Time Frame: 3 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Yale University | New Haven | Connecticut | - | - |
Find similar trials in New Haven, CT
By research site
Related Studies
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia AreataPHASE1/PHASE2 · Recruiting · Aldena Therapeutics · Thousand Oaks, California